Compugen Expects MAIA-Ovarian Clinical Data by Q1 2027 and Maintains Funding Through 2029
During its Q3 2026 earnings call, Compugen (CGEN) announced that it has successfully completed patient enrollment for the MAIA-Ovarian clinical trial. The company remains on schedule to report data from this study by the end of the first quarter of 2027. In addition to clinical progress, management provided updates regarding the company's financial runway, indicating that current funding plans are sufficient to support operations into 2029. This provides a long-term outlook for the biotechnology firm as it advances its pipeline.
Tickers: $CGEN